A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis
Authors:
- A. MunckAMA. Munck
- J.V. CraigJCJ.V. Craig
- I. SermetISI. Sermet
- K.G. BrownleeKBK.G. Brownlee
- M.J. SchwarzMSM.J. Schwarz
- C. CastellaniCCC. Castellani
- K.W. SouthernKSK.W. Southern
- 1 January 2009
- journal article
- review article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 8 (1) , 71-78
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practiceJournal of Cystic Fibrosis, 2008
- Is newborn screening for cystic fibrosis a basic human right?Journal of Cystic Fibrosis, 2008
- Diagnostic Sweat Testing: The Cystic Fibrosis Foundation GuidelinesThe Journal of Pediatrics, 2007
- A survey of newborn screening for cystic fibrosis in EuropeJournal of Cystic Fibrosis, 2007
- Sweat Testing Infants Detected by Cystic Fibrosis Newborn ScreeningThe Journal of Pediatrics, 2005
- Sweat‐testing in preterm and full‐term infants less than 6 weeks of agePediatric Pulmonology, 2005
- Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non‐carriersAmerican Journal of Medical Genetics Part A, 2005
- Variation in a Repeat Sequence Determines Whether a Common Variant of the Cystic Fibrosis Transmembrane Conductance Regulator Gene Is Pathogenic or BenignThe American Journal of Human Genetics, 2004
- Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation.Journal of Clinical Investigation, 1998
- DRIED-BLOOD SPOT SCREENING FOR CYSTIC FIBROSIS IN THE NEWBORNThe Lancet, 1979